SCHEMBL4379986

SCHEMBL4379986

COc1cccc(C(=O)Nc2nc3ccc(Oc4ccnc5cc(OC)c(OC)cc45)cc3s2)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCD O00767 11/20 0.71
MET P08581 1/20 0.68
MEN1 O00255 6/20 0.60
KMT2A Q03164 6/20 0.60
NPC1 O15118 5/20 0.60
RAB9A P51151 5/20 0.60
DHODH Q02127 1/20 0.60
KDM4E B2RXH2 2/20 0.58
ALDH1A1 P00352 2/20 0.58
HPGD P15428 2/20 0.58
LMNA P02545 1/20 0.58
TP53 P04637 1/20 0.58
ALOX15 P16050 1/20 0.58
TSHR P16473 1/20 0.58
ALOX12 P18054 1/20 0.58
HSD17B10 Q99714 1/20 0.58
SENP7 Q9BQF6 1/20 0.58
SENP6 Q9GZR1 1/20 0.58
PDGFRA P16234 1/20 0.56
KDR P35968 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4372037 0.92 SCD (0.69) SCDMETMEN1KMT2ANPC1
SCHEMBL30980881 0.92 SCD (0.69) SCDMETMEN1KMT2ANPC1
SCHEMBL4368604 0.92 MET (0.77) SCDMETMEN1KMT2ANPC1
SCHEMBL4368363 0.92 MET (0.66) SCDMETMEN1KMT2ANPC1
SCHEMBL4379203 0.92 MET (0.66) SCDMETMEN1KMT2ANPC1
SCHEMBL4379209 0.91 MET (0.70) SCDMETMEN1KMT2ANPC1
SCHEMBL4375037 0.89 MET (0.64) SCDMETMEN1KMT2ANPC1
SCHEMBL4366772 0.89 KDR (0.65) SCDMETKDR
SCHEMBL4374318 0.89 SCD (0.70) SCDMETMEN1KMT2ANPC1
SCHEMBL4373376 0.88 MET (0.66) SCDMETMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US disclosed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US disclosed
US-7626030-B2 Compounds and methods of use AMGEN INC. (US) 2009-12-01 US disclosed
US-20050245547-A1 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma AMGEN INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245547-A1 6-((6,7-Bis(methoxy)-4-quinolinyl)oxy)-N-(3-methylphenyl)-1-benzofuran-3-carboxamide;antiproliferative; -metastasis; -carcinogenic; -tumor; -inflammatory; -arthritic agents;hypotensive agents; myocardium necrosis; rheumatic diseases; tyrosine kinase inhibitors; antiallergens; asthma HGF, MET, HGFAC SCD 3456/4885MET 2/4885MEN1 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.